Showing 5791-5800 of 10174 results for "".
- Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasishttps://practicaldermatology.com/news/thermo-fisher-scientific-launches-corevitas-clinical-registry-in-generalized-pustular-psoriasis/2462265/Thermo Fisher Scientific announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RW
- Bimekizumab Not Linked with Depression, Suicidal Ideation in Moderate-to-Severe Psoriasishttps://practicaldermatology.com/news/mental-health-outcomes-in-patients-with-moderate-to-severe-psoriasis-treated-with-bimekizumab-analysis-of-phase-23-randomized-trials/2462260/A new analysis indicates that bimekizumab was not associated with a high risk of suicidal ideation/behavior (SIB) and depression. Psoriasis patients often face increased risks of SIB and depression, according to the researchers. Bimekizumab, an FDA-approved biologic inhibiting
- 595-nm Pulsed Dye Laser with 1565-nm Nonablative Fractional Laser Safe, Effective for Acnehttps://practicaldermatology.com/news/treatment-of-erythematous-acne-scars-using-595-nm-pulsed-dye-laser-combined-with-1565-nm-resurfx-nonablative-fractional-laser/2462257/The use of a 595-nm pulsed dye laser (PDL) and 1565-nm nonablative fractional laser (NAFL) was seen as safe and efficacious in patients with acne vulgarism, according to a new study in the Journal of Cosmetic Dermatology. "Acne erythema has been considered simple ery
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- La Roche-Posay Launches New Dark Spot Serumhttps://practicaldermatology.com/news/la-roche-posay-launches-dark-spot-serum/2462254/La Roche-Posay, a subsidiary of L'oreal, recently announced the launch of its new a new serum corrector for dark spots, the Mela B3 Dark Spot Serum with MelasylTM + Nicinamide. According to the manufacturer, the launch was preceded by 18 years of research, as well as rese
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A
- Analysis: Mix of Low- and Fair-quality Information for Hidradenitis Suppurativa Treatments on TikTokhttps://practicaldermatology.com/news/complementary-and-alternative-medicine-for-hidradenitis-suppurativa-discussed-on-tiktok-a-cross-sectional-analysis/2462251/Patients getting information on Hidradenitis suppurativa (HS) from TikTok were frequently exposed to low-quality information, a new study suggests. "Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease that negatively impacts quality of life," the
- Alvotech and Teva Announce US Approval of Simlandi, a Biosimilar to Humirahttps://practicaldermatology.com/news/alvotech-and-teva-announce-us-approval-of-simlandi-a-biosimilar-to-humira/2462250/Alvotech and Teva Pharmaceuticals announced the FDA approval of Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to blockbuster drug Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as&n
- Fear of Cancer Recurrence Elevated Among Survivors of Localized Cutaneous Melanoma: Analysishttps://practicaldermatology.com/news/lived-experiences-and-fear-of-cancer-recurrence-among-survivors-of-localized-cutaneous-melanoma/2462249/Patients who suffer from localized cutaneous melanoma report high levels of fear of cancer recurrence, according to a new analysis. Researchers investigating the psychological well-being and fear of cancer recurrence among survivors of localized cutaneous melanoma in the United States ev
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi